stockrow
Friday 6 November 2026
Export AZTR’s income statement to Excel — free account
Azitra, Inc.
AZTR Healthcare Biotechnology
Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023.
- EPS
- +85.3%
- Free cash flow
- −19.6%
Quarter to June 2026, against a year earlier
0.75
0.02
+2.74%
Follow AZTR
Alert me
Azitra, Inc. (AZTR) P/E ratio
As of 6 November 2026, Azitra, Inc. (AZTR) trades at a P/E ratio of 1.3×. Over the past ten years it has ranged from 0.0× (June 2026) to 3.2× (August 2026); the current reading is higher than 90% of that period. That is below the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2024 | 0.0× | — |
| Dec 2023 | 0.0× | — |
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 3.2×
Ten-year median
0.0×
Current reading's percentile
90
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OSRH OSR Health, Inc. compare | n/m |
| NCNA NuCana PLC Sponsored ADR compare | n/m |
| ADTX Aditxt, Inc. compare | n/m |
| NIKI Niki BioSolutions, Inc. compare | n/m |
| PMCB Nuvilex Inc. compare | n/m |
| SKYE Skye Bioscience, Inc. compare | n/m |
| CELZ Creative Medical Technology Holdings, Inc. compare | n/m |
| XBIO Xenetic Biosciences, Inc. compare | n/m |
| AZTR Azitra, Inc. | 1.3× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)